TKI anti HER1/EGFR and HER2/neu for COVID-19: living meta-analysis of clinical studies

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
deaths (OS)	0.62 [0.30, 1.27]	< 1	0%	1 study (1/-)	90.5 %	NA	not evaluable		crucial	-
deaths (OS) (extension)	0.84 [0.70, 1.01]	< 1	0%	3 studies (3/-)	96.6 %	some concern	not evaluable	moderate	important	-
RFS/DFS	0.84 [0.70, 1.01]	< 1	0%	1 study (1/-)	96.5 %	NA	not evaluable		important	-
events or deaths (EFS)	0.78 [0.47, 1.29]	< 1	0%	1 study (1/-)	83.4 %	NA	not evaluable		non important	-
events or deaths (EFS) (extended)	0.89 [0.66, 1.22]	< 1	0%	2 studies (2/-)	76.3 %	some concern	not evaluable	moderate	non important	-
pCR	1.42 [0.44, 4.60]	> 1	90%	2 studies (2/-)	71.9 %	some concern	not evaluable	moderate	non important	-
AE (grade 3-4) endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

breast cancer - HER2-positive, TKI anti HER1/EGFR and HER2/neu versus HER2 inhibitor, meta-analysis of study results

efficacy endpoints 00

AE (grade 3-4) endpoints 00